PF4 binds to nucleic acids and thereby exposes the epitope to which anti-PF4/heparin antibodies bind • PF4/aptamer complexes can induce an immune response resembling heparin-induced thrombocytopenia
Introduction
The chemokine platelet factor 4 (PF4) is released from platelet α -granules during platelet activation, 1 and binds, due to its high positive charge, to many negatively-charged polyanions, including heparin. PF4 forms large multimolecular complexes with heparin that are highly immunogenic. 2, 3 The resulting immunoglobulin G (IgG) antibodies are the cause of heparininduced thrombocytopenia (HIT), a prothrombotic adverse drug effect. 4 In HIT, multimolecular complexes comprised of PF4, heparin, and anti-PF4/heparin IgG cross-link platelet FcγIIa receptors, 5 triggering platelet activation, microparticle formation, and thrombin generation, with ~50% of affected patients developing thrombosis. 6 Recently, we showed that PF4 binds to polyanions on the surface of bacteria, thereby forming multimolecular complexes that are recognized by human anti-PF4/heparin antibodies.
More specifically, we identified the PF4 binding site on Gram-negative bacteria as the phosphate groups of lipid A. 7 Based on this observation, we hypothesized that nucleic acids might also form multimolecular complexes with PF4 because they also expose multiple negatively-charged phosphate groups. This idea was fostered by previous findings that salmon sperm DNA could substitute heparin in HIT-IgG induced platelet activation. 8 Plasma levels of extracellular nucleic acids are regulated by prompt nuclease degradation and renal clearance, resulting in their short half-life (4-30min), 9 with a slightly longer half-life for DNA than for RNA. In healthy individuals, extracellular nucleic acid concentrations in plasma range from 0 to >1000ng/mL. 10 However, under pathological conditions, cell-free nucleic acids can be generated from breakdown of bacteria and viruses, tissue damage, cell apoptosis, and release from blood cells such as formation of neutrophil extracellular traps (NETs). Plasma levels of extracellular nucleic acids can rise up to 2,000µg/mL. 11, 12 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 4 With the recent introduction of aptamers, small DNA/RNA constructs designed as therapeutic oligonucleotides, 13 the interaction of nucleic acids and PF4 becomes more relevant from a drug safety perspective. In this study, we characterize the structural features of RNA and DNA molecules, as well as aptamers, that are relevant for complex formation with PF4. We also demonstrate by circular dichroism (CD) spectroscopy that nucleic acids cause conformational changes in PF4 similar to those induced by heparin, and show that PF4/aptamer complexes can be highly immunogenic.
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Methods

Platelets and sera
Platelet-rich plasma was prepared from 10mL hirudinized whole blood (10µg/mL lepirudin, Pharmion, Hamburg, Germany), obtained from healthy blood donors (120g, 20min, 30°C).
Platelets were isolated by gel-filtration as described 14 and adjusted to 50×10 9 /L in Tyrode buffer (137mMNaCl, 2.7mMKCl, 2mM MgCl 2 x6H 2 O, 2mM CaCl 2 x2H 2 O, 12mM NaHCO 3 , 0.4mM NaH 2 PO 4 , 0.4% BSA, 0.1% glucose, pH 7.2). Sera containing anti-PF4/heparin antibodies were leftovers from clinical specimens used for laboratory diagnosis of HIT.
Nucleic acids and aptamers
Sequences and sources of aptamers and nucleic acid compounds are given in Figure-1 . Secondary structures were calculated by the mFold RNA and mFold DNA database of the University of Albany (N.Y., USA, http://mfold.rna.albany.edu/?q=mfold). The singlestranded 15mer-DNA thrombin aptamer targets thrombin; 15 the 44mer-DNA protein C aptamer inhibits activated protein C; 16 the 57mer-RNA tetracycline aptamer binds tetracycline; 17 and the 77mer-RNA flavin mononucleotide (FMN) aptamer is an artificial FMN-responsive catalytic RNA. 18 Cellular RNA and DNA were isolated from mouse vascular smooth muscle cells (MVSMC) using an extraction kit (Sigma, Munich, Germany) or the DNazol reagent (Invitrogen, Groningen, Netherlands).
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Binding of biotinylated RNA to PF4
Microtiter plates were coated with 50 µL solutions of PF4 or bovine serum albumin (10µg/mL each) in 100mM sodium carbonate (pH 9.5) at 4°C for 20h; washed and blocked (TBS, 3% BSA; 2h). Different concentrations of biotinylated RNA (0.78-25µg/mL), prepared from isolated cellular RNA using the Psoralen-PEO-Biotin reagent (Thermo Fisher Scientific
[Pierce], Rockford, N.Y.), were allowed to bind at 22°C for 2h, followed by three washes with TBS. Bound biotinylated RNA was detected using peroxidase-conjugated streptavidin (Dako, Glostrup, Denmark) and the immunopure 3,3',5,5'-tetramethylbenzidine (TMB) substrate kit (Pierce). In competition experiments, increasing concentrations of biotinylated RNA were mixed with unlabeled RNA, DNA or heparin (each at 300µg/mL) before binding assays were performed. To confirm that PF4 was not removed from the plate upon heparin addition, surface-coated PF4 was quantified by dot blot analysis and densitometry.
Influence of nucleic acids on PF4 binding to platelets
The impact of nucleic acids on binding of human platelet-derived PF4 (25µg/mL) (ChromaTec, Greifswald, Germany) to gel-filtered platelets (50,000/µL) was assessed by flow cytometry (Cytomics FC 500, Beckman Coulter, Krefeld, Germany) using a polyclonal FITClabeled rabbit anti-human PF4 antibody (Dianova, Marl, Germany), 14 in the absence or presence of unfractionated heparin (UFH; activity ~150IU/mg; Braun, Melsungen, Germany) or different nucleic acid compounds (0.08-640µg/mL; Figure 1 ). In parallel, RNA samples were treated with RNase A (100µg/mL, 90min, 37°C) (Fermentas, St. Leon-Rot, Germany) before addition to the respective test solution to document RNA dependency. Antibody binding was quantified by geometric mean fluorescent intensity.
PF4/nucleic acid enzyme immunoassay (EIA)
Binding of human anti-PF4/heparin IgG to PF4/nucleic acid complexes was assessed by EIA 19 using microtiter plates (Nunc, Langenselbold, Germany) coated (16h; 4°C) with preformed PF4/polyanion complexes: PF4 (20µg/mL) preincubated (1h, room temperature) with either UFH as positive control (3.33µg/mL), 15mer-DNA thrombin aptamer, 44mer-DNA protein C aptamer, 57mer-RNA tetracycline aptamer, or 77mer-RNA FMN aptamer in concentrations ranging from 1.25-80µg/mL. To find the optimal stoichiometric ratios for complex formation, we first titrated selected aptamers in the presence of a constant PF4 concentration in the EIA. As control for specific antibody binding, UFH (660µg/mL) was added to disrupt PF4/polyanion complexes and to inhibit antibody binding.
Platelet activation assay
Platelet activation by human anti-PF4/polyanion antibodies was assessed by the heparininduced platelet activation (HIPA) assay, as described, 20 using 0.2µg/mL heparin (positive control: reviparin; Abbott GmbH&Co. KG, Wiesbaden, Germany), deoxynucleotidetriphosphates (0.05-1,000µg/mL), 21mer-double-stranded DNA (0.05-1,000µg/mL), 21mer-hairpin DNA (0.05-1,000µg/mL), cellular RNA (0.05-5µg/mL), 15mer-DNA thrombin aptamer (0.5-40µg/mL), 44mer-DNA protein C aptamer (0.05-1,000µg/mL), 57mer-RNA tetracycline aptamer (0.5-5 µg/mL), and 77mer-RNA FMN-ribozyme (0.5-5µg/mL). To find the optimal concentrations for platelet activation, titration with the respective nucleic acid constructs in the HIPA test with one or two sera was performed, and then additional sera were assessed using this concentration. Specificity of platelet activation was confirmed by its inhibition using high concentrations of heparin (660µg/mL) that disrupts were anesthetized (2% xylazin/10% ketamin) and immunized as described 24 with recombinant murine PF4 (mPF4) (ChromaTec, Greifswald, Germany), 44mer-DNA protein C aptamer, mPF4/44mer-DNA protein C aptamer complexes (each at 200µg/mL), or complexes of mPF4 (200µg/mL) and heparin (33µg/mL) in a final volume of 100µL via retroorbital injection daily for five days. After another 10 days, blood was withdrawn and serum was analyzed for anti-mPF4/aptamer-or anti-mPF4/heparin antibodies, respectively, by EIA using mPF4/heparin and mPF4/44mer-DNA protein C aptamer complexes as antigens. 
Results
RNA binds to PF4
Binding of RNA to PF4 was assessed using biotinylated RNA, which bound to PF4 in a saturable manner, reaching a maximum at 6.25µg/mL ( Figure- 
RNA and DNA enhance PF4 binding to platelets
Next we assessed the interaction of PF4 and different nucleic acid constructs with gel-filtered platelets by flow cytometry, as previously described 14 for PF4-polysaccharide-platelet interactions. To analyze the structure-function relationship, RNA and DNA constructs of different length and structural complexity were tested. Figure-3 shows the influence of these constructs on PF4 binding to the platelet surface, whereby baseline binding was defined as PF4 binding to platelets in the absence of nucleic acids. Heparin, the prototype compound for PF4-polyanion interaction, increased PF4 binding to platelets in a dose-dependent manner, 
Aptamers enhance PF4 binding to platelets
We then investigated the influence of four different aptamers ( Figure- 
Aptamer-induced changes in PF4 resemble those induced by heparin
The impact of nucleic acids on the secondary structure of PF4 was analyzed using CDspectroscopy. The 44-mer-DNA protein C aptamer was used due to its nuclease-resistance.
Although changes in the PF4 structure induced by complex formation with the 44-mer-DNA protein C aptamer were similar to those induced by heparin, the most pronounced alterations of PF4 were observed at broader ranges of 44mer-DNA protein C aptamer (5-20µg/mL) compared with that seen with heparin (6.9-7.2µg/mL; Figure-5A ).
Deconvolution of the spectra of PF4 obtained after addition of 5µg/mL 44mer-DNA protein C aptamer or 6.9µg/mL heparin, respectively, showed an increase in anti-parallel β - 
Human anti-PF4/heparin antibodies bind to PF4/nucleic acid complexes
To assess whether complex formation between aptamers and PF4 also results in exposure of the same epitopes as on PF4/heparin complexes, we tested human sera known to contain anti- Immunization with mPF4 alone also caused an immune response (median OD 0.84, range 0.32-2.52; Figure-5E ), but this was significantly weaker than the immunization induced by mPF4/44mer-DNA protein C aptamer complexes (P=.015). The reason for an immune response to mPF4 alone is most likely formation of some mPF4-autoaggregates resembling mPF4/aptamer complexes as mPF4 tends to form spontaneous complexes in buffers with low 1 5 salt concentrations (unpublished observations). Antibody binding was always inhibited by addition of high concentrations of heparin. 1 6 
Discussion
In this study, we demonstrate a charge-and structure-related interaction between PF4 and nucleic acids and characterize the functional properties of these multimolecular complexes.
Nucleic acids induced structural changes in the PF4 molecule similar to those typically observed in PF4/heparin complexes. These structural changes resulted in the exposure of neoepitopes that were recognized by a subset of platelet-activating anti-PF4/heparin Besides charge density, the size of nucleic acids appears to be critical for enhancing binding of PF4 on the platelet surface. Longer constructs augmented PF4 binding to platelets ( Figure-3B ), while single nucleotides added at the same concentration did not. Similarly, 1 7 disaccharides do not bind to PF4, and the synthetic pentasaccharide, fondaparinux, binds only weakly to PF4. 32, 33 Although nucleic acids seem to share some similarities with heparins in regard to their polyanion character, the structure-function relationships for interactions between PF4 and nucleic acids appear to be more complicated. Other than heparins, nucleic acids can fold into highly organized structures, e.g., those exhibiting spatial clustering of negative charges. While several RNA-and DNA-constructs formed complexes with PF4, the linear homopolymers 45mer-polyA and 45mer-polyC did not (Figure-3) , although they were above the critical length and showed a high charge density. Thus, double-stranded domains within nucleic acids seem to be important for binding to PF4. This is in line with our recent observations that double-stranded hairpin-forming, but not single-stranded, nucleic acid oligomers are also potent activators of the intrinsic coagulation pathway by interacting with the RNA-binding cofactor high molecular weight kininogen. 34 
Figure-6 depicts a simplified model of the interaction between PF4 and nucleic acids:
the negatively-charged phosphate residues along the backbone of double-stranded nucleic acids bind to PF4, just as PF4 binds to the sulfate groups of heparin ( Figure-6A-B) . In contrast, due to their higher flexibility and the loose spatial arrangement of negative charges, single-stranded nucleic acids are more likely to wrap around one PF4 tetramer instead of bridging several PF4 tetramers (Figure-6C ). This is mediated by interactions of their phosphate groups with positively-charged amino acid residues of PF4, as it has already been described for polysaccharides comprising >34 sugar units. 35 However, the molecular interactions are likely more complex and certain conformations of nucleic acids appear to be more prone than others to form multimolecular complexes with PF4. One example is the reactivity of the 44mer DNA protein C aptamer versus the 77mer RNA FMN aptamer. Although the latter is much longer and has more 1 8 double-stranded segments (Figure-1A) , anti-PF4/heparin antibodies bound somewhat stronger to PF4/44mer Protein C aptamer complexes (Figure-5D ).
Our data raise further questions beyond the scope of the current study. It remains unclear why only about 60% of the anti-PF4/heparin antibodies which induced platelet activation in the presence of heparin also caused platelet activation in the presence of nucleic acids. Even more puzzling is our observation that those sera that induced platelet activation in the presence of nucleic acids did so with most nucleic acids, independent of whether these strongly enhanced PF4 binding to the platelet surface or not. In the absence of a three dimensional model of the structural changes of PF4 induced by different nucleic acids, we can only speculate that the nucleic acids may expose different epitopes than heparins do.
Another hypothetical explanation could be based on the recent studies of Sachais et al, 36 showing that the monoclonal antibody KKO, but not another anti-PF4 monoclonal antibody, is able to induce oligomerization of PF4 also in the absence of heparin, suggesting that some anti-PF4/heparin antibodies are capable of promoting further formation of their own antigen. 37 Following this concept, sera causing platelet activation in the presence of nucleic acids might contain antibodies which-like KKO-can crosslink PF4 molecules. In this case, the negative charge of nucleic acids would initiate antigen formation by allowing close approximation of PF4 molecules which would be sufficient for further oligomerization of PF4 by such anti-PF4/heparin antibodies. Unfortunately, we cannot readily test these hypotheses experimentally due to the polyclonal nature of human antibodies.
Despite these unresolved issues, our study provides an explanation for why patients with major tissue damage develop increased levels of anti-PF4/heparin antibodies compared to patients with minor tissue damage. 38 Increased concentrations of cell-free plasma DNA (1-2µg/mL) have been found in various clinical conditions, including trauma, 39 cancer, 40 and infections, 41 correlating with the severity of trauma or infection. 11, 41 However, due to their 1 9 short plasma half-life elevated RNA/DNA-plasma levels return to baseline within a few hours after tissue damage. Yet this might be sufficient to induce an immune response, as also single and minimal applications of heparin have been shown to be sufficient for induction of HIT. 42 Cellular RNA and DNA released by the tissue trauma might complex with PF4, potentially enhancing the immune response against PF4/heparin complexes. In vivo formation of PF4/nucleic acid complexes may also explain the formation of anti-PF4/heparin antibodies in patients after major orthopedic surgery even in the absence of heparin, [43] [44] [45] as well as the relatively high frequency of antibodies in critically ill patients. 46 In addition, formation of PF4/nucleic acid complexes might be another explanation for the reported cases of immunogenic when given to patients with major proinflammatory states, such as following surgery 49 or major trauma 38 . Thus, studies of aptamer administration in healthy volunteers could be expected to underestimate the anti-PF4/aptamer immune response that could occur in patients. The evaluation of the anti-PF4/polyanion immune response within clinical studies is a far more sensitive marker of evaluating the potential of a given aptamer for inducing serious adverse effects than is monitoring for thrombocytopenia and thrombosis.
While induction of an immune reaction resembling typical HIT may be rather unlikely due to the usually low plasma concentrations of aptamers, a strong antibody response to PF4/aptamer complexes may result in an immune reaction resembling "delayed onset HIT", 50 an autoimmune-like syndrome in which strongly reactive anti-PF4/polyanion antibodies activate platelets and induce thrombosis even in the absence of heparin. Yet various aptamers differ considerably in their structure and are often chemically modified, which may interfere with their binding to PF4. Using the methods described in this study, it should be possible to screen aptamers for their potential interaction with PF4. We suggest that clinical trials of aptamers or other therapeutic nucleic acid constructs should include screening for the development of anti-PF4/aptamer antibodies and potential clinical features of HIT as part of their safety endpoints. 
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Figure 6: Schematic model of complex formation between PF4 and nucleic acids.
A) The basic amino acid residues (+) in the PF4-tetramer interact with the negatively-charged phosphate groups (-) in double-stranded nucleic acids, thereby forming large multimolecular complexes. B) PF4 binds to the negatively-charged sulfate groups (-) on both sides of the heparin molecule, resulting in the formation of large multimolecular complexes. C) Due to their high flexibility, single-stranded nucleic acids potentially wrap around PF4-tetramers, thereby inhibiting the formation of large, multimolecular complexes with PF4.
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